Forward Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Forward Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-172,300	Closed	-$2.2M	–	420
2014 Q4	$2.2M	Buy	+172,300	New	+$2.04M	0.12%	104

Other funds holding VNDA

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Forward Management's VNDA Position: Q1 2015 in Review

Forward Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2015, closing a stake of 172,300 shares — an estimated $2.2M sold.

Forward Management first reported a position in VNDA in Q4 2014 and held it in 1 quarter. The position peaked at $2.2M in Q4 2014. 110 funds tracked by Wall St. Rank hold VNDA as of Q1 2015.

Forward Management reported no remaining Vanda Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Forward Management sold 172,300 Vanda Pharmaceuticals shares in Q1 2015, an estimated $2.2M.
Forward Management first reported a position in Vanda Pharmaceuticals in Q4 2014 and held it in 1 quarter.
Forward Management's Vanda Pharmaceuticals position peaked at $2.2M in Q4 2014.
110 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2015.

Based on Forward Management's 13F filing for Q1 2015, filed 14 May 2015.